Disease-modifying therapies (DMTs) in MS patients are associated with a decreased immune response to antigens. A post-SARS-CoV-2 vaccination serological assessment was performed to examine the antibody response in MS patients treated with DMTs as compared with untreated patients. The current analysis of this prospective, multicentre cohort study assessed 1,339 MS patients (treated with a DMT, n=1,166; untreated, n=173) who received 2 doses of SARS-CoV-2 mRNA vaccines (Pfizer/BioNTech or Moderna). Blood samples were collected before the 1st dose, and 4 weeks after the 2nd dose. A centralised, blinded serological assessment was performed at each timepoint. Prof. Maria Pia Sormani (University of Genoa, Italy) shared the results.
Multivariate analysis revealed decreased antibody levels in patients treated with ocrelizumab (231-fold decrease, P<0.001), rituximab (20-fold decrease, P<0.001), or fingolimod (32-fold decrease, P<0.001) compared with untreated patients. Notably, patients on anti-CD20 (ocrelizumab/rituximab) therapies developed higher antibody levels when the time to the last administered infusion was longer. Patients who received the Moderna vaccine developed significantly higher antibody levels (2.9-fold) compared with those who received Pfizer/BioNTech (P<0.001). A booster vaccine may therefore be beneficial for patients with low antibody levels.
- Sormani MP. Effect of SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with disease modifying therapies. OP099, ECTRIMS 2021 Virtual Congress, 13–15 October.
- Sormani MP, et al. EBioMedicine. 2021;72:103581.
Copyright ©2021 Medicom Medical Publishers
Posted on
Table of Contents: ECTRIMS 2021
Featured articles
Preliminary data shows positive results of ATA188 for progressive MS
COVID-19
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
Experimental Treatments
The role of astrocyte phenotypes in acute MS lesions
Promising results of intrathecal MSC-NTF cells in progressive MS
Preliminary data shows positive results of ATA188 for progressive MS
Evobrutinib reduces relapses and MRI lesion activity
Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial
Elezanumab did not outperform placebo in progressive and relapsing MS
Ibudilast reduced retinal atrophy in primary progressive MS
Treatment Trials and Strategies
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
Rituximab most effective initial MS therapy in Swedish real-world study
Ublituximab meets primary endpoint for relapsing MS
Dynamic scoring system aids decision to switch MS therapies early
Long-term suppression of MRI disease activity with ocrelizumab
Stopping DMT: when or if at all?
Biomarkers
Early predictors of disability progression in paediatric-onset MS
High-sensitive biomarker detection in MS via novel ELISA assay
Cortical lesions predict cognitive impairment 20 years after MS diagnosis
Applicability of sNfL measurement in clinical practice
MRI more sensitive for disease activity than relapses in SPMS
Imaging
Changes in GABA-receptor binding among cognitively impaired MS patients
T2 lesions independently predict early conversion to SPMS
Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Eculizumab, satralizumab, or inebilizumab for NMOSD?
Long-term efficacy of satralizumab for NMOSD
Long-term efficacy data: inebilizumab for NMOSD
Progressive MS
Charcot Award 2021: Progressive MS, a personal perspective
Top score poster: Meta-analysis on the effect of DMTs
Cortical lesions predict disease progression and disability accumulation
Ocrelizumab shows long-term benefits in primary progressive MS
Other
WNT9B-gene variant associated with doubled relapse risk in MS
Melatonin associated with improved sleep quality in MS patients
“Expanded Disability Status Scale 0 is not normal”
Personality trait alterations in MS patients
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com